but research implicates these pathways as a possible therapeutic approach to Ang-II-induced pathologies.
This review investigates pathological and therapeutic mechanisms induced by the RAS axes and exercise within skeletal muscle.
To accomplish this, the review of literature is organized below by each pathway of interest: Oxidative stress, Ubiquitin Proteasome System (UPS), Protein Synthesis and Fibrosis. The review will also provide insight into possible protein targets for future research and therapeutic products.
| S EC TI ON 1: RE AC TIVE OX YG EN S PECIE S

| Angiotensin II-induced ROS production
Oxidative stress is one of the most studied mechanisms of skeletal muscle atrophy. It is the result of increased reactive oxygen species (ROS) production in skeletal muscle leading to atrophy through multiple mechanisms such as inducing apoptosis, increasing proteolysis and decreasing protein synthesis. 5, [13] [14] [15] [16] [17] Ang-II-mediated increase in muscle ROS production occurs, at least in part, due to AT 1 R-mediated increases in both NADPH oxidase (NOX) activity and elevated mitochondrial ROS production leading to the speculation that NOX/mitochondrial cross-talk exists in skeletal muscle exposed to high levels of Ang-II. 1, 13, 18 Regardless of the cellular site(s) of Ang-II-induced ROS production in skeletal muscles, it is established that oxidative stress contributes to inactivity-induced muscle atrophy by increasing proteolysis, increasing myonuclear apoptosis and depressing protein synthesis. 19 After 4 weeks of Ang-II infusion, mice lacking the expression of NOX2 exhibited no skeletal muscle atrophy. 5 However, the wild-type mice infused with Ang-II exhibited skeletal muscle atrophy. 5 This study also indicates that skeletal muscle apoptosis may not be caused by NOX2-derived ROS because the only group not showing an increase in apoptosis was the wild type infused vehicle mice. 5 This study suggests that there are alternative ROS that may only activate certain pathways.
ROS can act upon multitude pathways, one of which leads to impaired glucose uptake and desensitization of insulin within skeletal muscle. 20 Impaired glucose uptake and insulin sensitivity cause a decline in adenosine triphosphate (ATP) production, which creates an imbalance between protein degradation and synthesis. 13, 21 When ATP is in short supply, protein degradation increases to scavenge necessary products to make ATP. 22 This mechanism has two possible pathways and both involve the interaction with protein kinase B (Akt). Akt, when activated, initiates protein synthesis and can inhibit protein breakdown. 23 ROS inhibits phosphorylation of Akt and decreases this protein's activity causing a decrease in skeletal muscle protein synthesis and increase in protein degradation. 4, 5 By decreasing Akt activity, glucose transporter 4 (GLUT4) translocation is inhibited resulting in decreased glucose uptake and insulin sensitivity. 20 The other pathway leading to the inhibition of GLUT4 translocation is caused by the increase in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) initiated by ROS. 18 NF-intracellular directly acts upon Akt and decreases its activity; Akt inhibition leads to an increase in NF-intracellular, which further inhibits Akt and continuously drives the inhibition of GLUT4 translocation. Figure 1 illustrates previously mentioned mechanisms of Ang-II-induced ROS production and two muscle damaging pathways that ROS affects.
Degradation of mitochondria and skeletal muscle can initiate proteolysis machinery within the ubiquitin proteasome system. This system can be initiated by ROS and Ang-II, the mechanisms involved in the upregulation of proteolysis will be described in Section 2. As described in the previous section, Ang-II decreases Akt activity leading to the inhibition of GLUT4 translocation. 18 Ang-II can directly cause the inhibition of GLUT4 relocation by inhibiting activated protein kinase (AMPK) activity by increasing protein phosphatase 2C alpha (PP2Cα) 31 or through the production of NF-κB and ROS, which directly inhibits Akt activity, which is needed for GLUT4 relocation. 5, 32 Ang 1-7's ability to increase Akt activity could be the result of declines in ROS. Research indicates that Ang 1-7 does not decrease pre-existing ROS levels, suggesting that Ang 1-7 directly inhibits NOX activity. 9, 29, 32 Although it seems that ROS is responsible for the initiation of previously described pathogenic pathways, one cannot rule out the other proteins that decrease Akt activity, such as NF-κB and caspase-3. With that in mind, Ang 1-7-induced increase in glucose uptake and insulin sensitivity could be a result of the inhibition of NF-κB, caspase-3 and ROS production. 30, 33 The ability to distinguish mechanisms not associated with ROS is difficult. NOX has been suggested as the primary ROS producer by experiments inhibiting NOX, resulting in the decline of the aforementioned mechanisms 3, 14, 18 ; however, mitochondrial dysfunction also leads to ROS production, which can reestablish these pathological pathways, establishing the second feedback loop. 15 
| Angiotensin 1-7 may decrease ROS production and resulting oxidative damage
| Exercise can attenuate Ang-II-induced oxidative damage
Exercise is associated with an increase in health and wellness, which is linked with the decrease in oxidative stress. [37] [38] [39] [40] Like Ang 1-7, exercise can be used as a therapeutic outlet for those suffering from illnesses associated with high levels of Ang-II. Research indicates exercise can combat decreased insulin sensitivity, glucose uptake, fibre type alterations and mitochondrial dysfunction caused by ROS. [37] [38] [39] This normalizes skeletal muscle function, producing proper protein degradation and protein synthesis.
Exercise has been shown to alter Ang-II-induced effects on Akt to promote proper glucose uptake and insulin sensitivity in skeletal muscle. 37, 41 Exercise could stimulate Akt activity in three ways:
through insulin-like growth factor-1 (IGF-1) signal transduction, 37 increased activity of AMPK 41, 42 or directly reducing oxidative stress. 43 AMPK might not directly interact with Akt, but increasing The mechanism for this pathway will be described in Section 3 as this pathway involves more than improving GLUT4 translocation. Whether AMPK directly influences Akt activity is still unclear; however, since Akt is the intersection for many mechanisms, this is certainly worth investigating.
Ang-II/ROS-induced loss in muscular function, size and fibre type alterations can be blunted with exercise. 46 The pathway involving the increase in PGC-1α is described in Section 2 and is linked to the prevention of muscle loss and dysfunction. 31, 42, [46] [47] [48] [49] Research indicates that exercise can prevent ROS-related muscle damage and reestablish normal phenotype. 38 Although the experiments have failed to look at ion channel operations in a ROS + exercise model, there may be a link to exercise improving the in/outflow of these channels, as exercise has been shown to improve membrane conductance. 9 Exercise could be exerting some of these antioxidant effects through Ang 1-7. Gomes-Santos 10 indicated exercise could increase Ang 1-7/Ang-II ratio and decrease AT 1 R among chronic heart failure rats. This line of research suggests exercise-related mechanisms can be due in part to the direct manipulation of ACE2/Ang 1-7/Mas axis.
This further suggests the effectiveness of exercise as a therapeutic prescription.
| S EC TI ON 2: UB I QU ITIN PROTE A SOME S YS TEM
| Angiotensin II increases protein degradation and mitochondrial dysfunction
The mechanism of Ang-II-induced atrophy via up-regulation of the ubiquitin proteasome system (UPS) is a complicated and a controversial pathway. Most research indicates that Ang-II directly stimulates the atrophic state via AT 1 R 13, 18, 47 ; however, others claim that Ang-II-induced atrophy is caused by the up-regulation of glucocorticoids. 49 Although the Ang-II-induced glucocorticoid pathway leading to atrophy has been refuted 35 The complexity of the mechanisms leading to atrophy represents the difficulty in proper treatment, which is why many treatments involve ACE or AT 1 R inhibition in an attempt to prevent these mechanisms leading to atrophy.
| Angiotensin 1-7 inhibits p38MAPK and IKK and decreases protein degradation activity
Little is known regarding mechanisms underlying the downregulation of protein degradation via Ang 1-7/MasR in skeletal muscle. Application of 
| Exercise promotes ATP generating pathways
Exercise can inhibit protein degradation in a similar fashion as Ang Ang-II decreases PGC-1α causing both muscle fibres types to rely primarily on anaerobic metabolic pathways for ATP production.
This process can lead to a decrease in exercise capacity, 15 
| S EC TI ON 3: PROTEIN SYNTHE S IS
| Angiotensin II inhibits Akt and may interact with p53
Along with an increase in protein degradation, Ang-II-induced pathogenesis impacts protein synthesis. Ang-II inhibits Akt, which As discussed earlier AMPK activity is inhibited by Ang-II, but under normal conditions, the increase in AMPK activity can inhibit protein synthesis to promote ATP production. 
| Angiotensin 1-7 improves IGF-1/IGF-1R signal transduction
As discussed previously, Akt activity plays an important role in activity, 60 which leads to increased protein synthesis via increased levels of P70S6K. Inhibiting FOXO1 prevents the increase in IKK activity and translocation of NF-κB. Akt activity also leads to an inhibition of glycogen synthase kinase-3 beta (GSK-3β), which down-regulates glycogen synthase activity and promotes protein synthesis. 22 Section 1 noted the ability for Akt to allow GLUT4 translocation leading to improved glucose sensitivity and influx of glucose into skeletal muscle. This influx of glucose produces ATP via glycolysis. ATP production provides the energy that is needed for protein synthesis to occur. Under Ang-II-induced pathology, ATP is depleted which drives the offset between protein degradation and synthesis. Although actions of Ang 1-7 are still unclear, the signal transduction of Ang 1-7 might be able to inhibit AMPK and further promote protein synthesis. Figure 3 illustrates Ang 1-7 mechanisms inhibiting NOX activity, increasing ATP production and protein synthesis.
| Exercise improves autophagy regulation
Like Ang 1-7, Exercise improves Akt activity via IGF-1 signal transduction, which improves protein synthesis. 22 Exercise improves autophagy regulation through Akt/FOXO3 signalling. 37 Ang-II primarily drives fibrosis through NOX-derived ROS 32 ; ROS increases p38MAPK activity which in turn increases transforming growth factor-beta (TGF-β) expression. 6 The increase in p38MAPK
coincides with an increase in extracellular signal-regulated kinase 1/2 (ERK1/2) activity. 6 ERK1/2 has been linked to a variety of cellular responses but with regards to fibrosis, ERK1/2 is a suggested link to an increase in fibronectin, collagen and TGF-β synthesis. 6,7 ERK1/2 also activates the Smad2 and Smad3 complex, which forms a complex with Smad4 and translocates to the nucleus. 45 The translocation of TGF-β can stimulate skeletal muscle cells along with Ang-II to further enhance fibrosis. TGF-β has been found to increase ROS production and provides a strong stimulus for the generation CTGF.
CTGF has also been shown to induce fibrosis through the interaction with AT 1 R. In addition to the ability of TGF-β to contribute to the production of fibrotic factors, TGF-β can also stimulate NOX-activated ROS and contribute to atrophy. 6, 32, 62, 64, 65 
| Angiotensin 1-7 reduces fibrotic factors
Fibrotic deposition is regulated by the actions of Ang 1-7 and contributes to anti-fibrotic process through the inhibition of NOX. By preventing ROS production, Ang 1-7 decreases activated ERK1/2 proteins thus preventing synthesis of fibrotic agents. 
| Exercise increases SOD and myofibres which can prevent fibrotic deposition
Fibrosis can be regulated by exercise by improving oxidative properties of skeletal muscle and by inhibiting the actions of NF-κB, which stimulates an increase in the inflammatory cytokine TNF-α. 41, [69] [70] [71] Inflammation is an indication of muscular remodelling, which exercise can regulate by increasing in I-kappa-B-beta/alpha (IKB-β/α), which actively inhibits NF-κB activity. 41 This indicates exercise as a logical way to restrict the pathogenic actions of Ang-II.
As stated previously, exercise also regulates the expression of 
| CON CLUS ION
Ang-II disrupts skeletal muscle function by increasing NOX-derived ROS leading to the imbalance between protein degradation and synthesis. The muscle lost due to atrophy is replaced by fibrotic deposition, which further impairs skeletal muscle function. Ang 1-7 and exercise work to normalize and maintain skeletal muscle function.
Ang 1-7 has been shown to inhibit Ang-II stimulation of NOX, which prevents ROS production allowing for normal skeletal muscle functioning. Exercise increases antioxidant enzymes, which decreases intracellular ROS. Exercise also increases PGC-1α activity, which improves skeletal muscle oxidative metabolism. Improved oxidative metabolism allows the muscle to clear ROS and ultimately reduce oxidative stress-related damage.
Future research should investigate how the RAS axes are affected in skeletal muscle by long-term exercise and Ang 1-7. Overall, more research is needed to properly identify the mechanism related to the therapeutic role of Ang 1-7 and exercise within skeletal muscle.
Currently no research has investigated Ang 1-7 or exercise effects on ion channels within skeletal muscle under Ang-II-induced pathology.
This could provide better treatment strategies for patients suffering from Ang-II-induced pathologies. Current treatments typically consist of angiotensin receptor blockers (ARBs) or ACE inhibitors, which are good for short-term prevention but do not make lasting physiological changes to the skeletal muscle such as exercise would. 
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